Upcoming Webinars 2025
1st April
7pm to
9pm
Navigating Menopause:
Early Diagnosis and Effective Management of Vaginal Atrophy (VA) and GSM
- Diagnosing VA, what to look for?
- Managing your VA patients
- Q&A
- For more information please click below.
Give your patients rapidly effective treatment for the symptoms of vaginal atrophy with Blissel®1-3
Treatment for vaginal atrophy is an unmet need
About 50% of postmenopausal women have pain or discomfort caused by vaginal atrophy, which can have significant effects on their quality of life and personal relationships.4,5
Diagnosis of vaginal atrophy may be complicated by the various ways in which it can present, including vaginal dryness, dysuria, itching, burning, and pain during sex.6
Half of all women with postmenopausal genitourinary symptoms have not been prescribed any therapies for their symptoms.7
Blissel® is designed to provide relief from vaginal atrophy symptoms
Blissel® uses a formulation of polycarbophilic components to produce a mucoadhesive gel.3 This gives a moisturising effect, whilst also ensuring that the active hormone is retained.3
Non-mucoadhesive products may have shorter vaginal tissue contact time and may cause leakage.3
Blissel® has an included applicator, to allow women to administer the treatment for a comfortable and mess-free solution.1
Guidelines clearly advocate for vaginal atrophy treatment for women
The British Menopause Society suggests prescribing the lowest HRT dose that will effectively manage a patient’s symptoms.8
NICE guidance is to offer patients topical vaginal oestrogens to manage the symptoms of vaginal atrophy.9
My BlisselⓇ Time to talk
Video Library
A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics, including How Blissel® works, the time until Blissel® takes effect, and how to use an applicator.
The Blissel® formulation may have multiple beneficial effects
Blissel® uses polycarbophilic components to form a mucoadhesive gel, which leads to a moisturising effect whilst also increasing retention of the active hormone ingredient.3
Products which are not mucoadhesive may be in contact with the vaginal tissues for a shorter time and may lead to leakage.3
The British Menopause Society suggests that patients should be given the lowest HRT dose that will effectively manage their bothersome symptoms.4
Low dose estriol formulations, such as Blissel®, have a lower systemic absorption than medications which contain a higher hormonal dose.10
With Blissel®, women do not have a long wait for relief
Blissel® can give your patients a rapid improvement in their symptoms from the first days of treatment.3
Prescribe Blissel® by brand for your patients. Blissel® is the first and only prescribable estriol containing gel for the treatment of vaginal atrophy.1,2
How BlisselⓇ
Works
Efficacy
Dosing
Ultra low dose estriol vaginal gel1,2
Prescribing and Adverse event reporting information for BlisselⓇ can be found here.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com
1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics. 2. Cano A, et al. Menopause. 2012;19(10):1130-9. 3. Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69. 4. Nappi RE, Palacios S. Climacteric. 2014;17:3–9. 5. Moral E, et al. Menopause. 2018;25(12):1418-23. 6. Palmaa F, et al. Maturitas. 2018;108:18–23. 7. NAMS position statement. Menopause. 2020;27(9):976-92. 8. British Menopause Society Women’s Health Concern Fact Sheet: HRT Benefits and Risks; November 2017. 9. NICE. Menopause: diagnosis and management (NG23). Available from: https://www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed November 2024. 10. Delgado JL, et al. Climacteric. 2016;19(2):172-80.
Date of preparation: March 2025 | UK-BLS-609h